Immunosuppressive therapy of childhood idiopathic nephrotic syndrome.

Abstract:

:Childhood nephrotic syndrome (NS) is a distressing chronic renal disorder with potentially life threatening complications. Over 80% of cases in children are due to minimal change disease and the majority will respond to corticosteroid therapy. Steroid-sensitive NS is considered a relatively benign condition, since progression to end stage renal failure (ESRF) is extremely rare and > 80% will enter spontaneous long-term remission in later childhood. However, the disease is characterised by a relapsing course, placing the child at risk of acute complications, such as infection, hypovolaemia and thrombosis. Frequent relapses can result in a not inconsequential corticosteroid burden or prescription of cytotoxic immunosuppressive therapy to control the disease. In contrast, steroid-resistant and -refractory NS has an unfavourable outcome with a propensity to progress to ESRF. While these clinical entities have an unpredictable response to cytotoxic immunosuppressive therapy, the favourable long-term renal survival associated with children who enter sustained remission has revived the enthusiasm to treat steroid-resistant NS with more aggressive immunosuppressive regimens.

authors

Abeyagunawardena A,Brogan PA,Trompeter RS,Dillon MJ

doi

10.1517/14656566.3.5.513

keywords:

subject

Has Abstract

pub_date

2002-05-01 00:00:00

pages

513-9

issue

5

eissn

1465-6566

issn

1744-7666

journal_volume

3

pub_type

杂志文章,评审
  • Pharmacoeconomic considerations in anticoagulant drug use.

    abstract::Anticoagulants are used for the prevention and treatment of venous thromboembolism and for the secondary prevention of stroke and myocardial infarction. The list of available anticoagulants includes unfractionated heparin, low molecular weight heparins, fondaparinux, warfarin and the direct thrombin inhibitors. Numero...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.8.989

    authors: Hawkins D,Huston SA

    更新日期:2006-06-01 00:00:00

  • Dapagliflozin for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Despite the availability of many antihypreglycemic agents, many patients with type 2 diabetes (T2DM) fail to achieve the glycemic treatment goal, primarily due to progressive beta-cell dysfunction, and increased risk of hypoglycemia. AREAS COVERED:The aim of the present article is to review the efficacy a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.812632

    authors: Abdul-Ghani MA,DeFronzo RA

    更新日期:2013-08-01 00:00:00

  • Treatment of steroid-naive ulcerative colitis.

    abstract::The introduction of steroid therapy by Truelove and Witts in the 1950s revolutionized the treatment of ulcerative colitis. Corticosteroids are potent inhibitors of T-cell activation and proinflammatory cytokines and still represent the mainstay of therapy of patients with ulcerative colitis. About 15% of patients are ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902973728

    authors: Bossa F,Colombo E,Andriulli A,Annese V

    更新日期:2009-06-01 00:00:00

  • Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.

    abstract::Venous thromboembolism is a frequent, life-threatening, postoperative complication of hip-fracture and total-knee-replacement surgery. Fondaparinux is a synthetic polysaccharide that selectively binds to antithrombin, the primary endogenous regulator of blood coagulation. Low molecular weight heparins, such as enoxapa...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,杂志文章,评审

    doi:10.1517/14656566.3.4.455

    authors: Doggrell SA

    更新日期:2002-04-01 00:00:00

  • Cost-effectiveness of widespread screening for Chlamydia trachomatis.

    abstract::Screening for sexually transmitted diseases is included in routine health care for several infectious agents in many western European countries. Current considerations on extensions of these programs include widespread screening strategies for Chlamydia trachomatis. In women, C. trachomatis infection may lead to seque...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.10.1443

    authors: Postma MJ,Welte R,Morré SA

    更新日期:2002-10-01 00:00:00

  • Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease.

    abstract:INTRODUCTION:Alzheimer's disease (AD)-related epileptic comorbidity is now well documented and appears to have been previously underestimated. Prescribing antiepileptic drugs (AEDs) in AD patients aims at preventing seizure-related morbi-mortality and the occurrence of deleterious status epilepticus. At the earlier sta...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1496237

    authors: Cretin B

    更新日期:2018-08-01 00:00:00

  • Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.

    abstract:INTRODUCTION:In this review, the authors describe medications in phase III of clinical development for schizophrenia and schizoaffective disorder, and provide an opinion on how current treatment can be improved in the near future. AREAS COVERED:Recent (post 2013) phase III clinical trials of schizophrenia-targeted the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1149164

    authors: Garay RP,Citrome L,Samalin L,Liu CC,Thomsen MS,Correll CU,Hameg A,Llorca PM

    更新日期:2016-01-01 00:00:00

  • Current and emerging drug treatment strategies for peripheral arterial disease.

    abstract:INTRODUCTION:Peripheral artery disease (PAD) is a prevalent but underdiagnosed manifestation of atherosclerosis that has a worse prognosis than coronary artery disease. Patients with PAD are at heightened risk of both systemic cardiovascular adverse events and limb-related morbidity. There is insufficient awareness of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1774556

    authors: Essa H,Torella F,Lip GYH

    更新日期:2020-09-01 00:00:00

  • Advancing treatment options for chronic idiopathic constipation.

    abstract:INTRODUCTION:Chronic constipation is a global problem affecting all ages and associated with considerable morbidity and significant financial burden for society. Though formerly defined on the basis of a single symptom, infrequent defecation; constipation is now viewed as a syndrome encompassing several complaints such...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1127356

    authors: Quigley EM,Neshatian L

    更新日期:2016-01-01 00:00:00

  • Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.

    abstract:BACKGROUND:This study aimed to analyze the characteristics and outcomes of patients suffering from non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor mutations (EGFRm+) receiving gefitinib who remained clinically stable following confirmation of progressive disease (PD) using Response Evaluation C...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1484903

    authors: Hosomi Y,Tanai C,Yoh K,Goto Y,Sakai H,Kato T,Kaburagi T,Nishio M,Kim YH,Inoue A,Hasegawa Y,Isobe H,Tomizawa Y,Mori Y,Minato K,Yamada K,Ohashi Y,Kunitoh H

    更新日期:2018-07-01 00:00:00

  • Flecainide acetate for the treatment of atrial and ventricular arrhythmias.

    abstract:INTRODUCTION:Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982. The clinical development program of flecainide provided good data on its antiarrhythmic effect for the prevention of ventricular and supraventricular arrhythmias. The Cardiac Arrhythmia Suppression Trial (CAST), conducted to test...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.759212

    authors: Apostolakis S,Oeff M,Tebbe U,Fabritz L,Breithardt G,Kirchhof P

    更新日期:2013-02-01 00:00:00

  • Summarizing the FIELD study: lessons from a 'negative' trial.

    abstract:INTRODUCTION:Disturbances in lipid metabolism represent an integral component of dysglycemic states and may increase the risk of diabetic complications. Although from a pathophysiological viewpoint fibrates could represent the ideal drug for patients with diabetic dyslipidemia the evidence that support their use in the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.850075

    authors: Tsimihodimos V,Mikhailidis DP,Elisaf M

    更新日期:2013-12-01 00:00:00

  • Clinical management of chronic obstructive pulmonary disease and asthma in an obese patient.

    abstract::The prevalence of obesity has noticeably increased worldwide. The clinician is now frequently facing the challenge of managing patients with concomitant chronic obstructive pulmonary disease (COPD) or asthma and obesity. Obesity is often associated with a poorer control of these chronic respiratory diseases and the op...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.1.83

    authors: Lessard A,Maltais F,Boulet LP

    更新日期:2008-01-01 00:00:00

  • Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline.

    abstract::Sertraline (Zoloft, Pfizer Inc.) is a selective serotonin re-uptake inhibitor (SSRI) which has been approved by the US FDA for the treatment of premenstrual dysphoric disorder (PMDD). PMDD is a severe form of premenstrual syndrome (PMS) which affects at least 5 - 8% of women of reproductive age. It is characterised by...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.11.2065

    authors: Halbreich U,Kahn LS

    更新日期:2003-11-01 00:00:00

  • A comparative evaluation of properties and clinical efficacy of the echinocandins.

    abstract::With the increase in prevalence of fungal infections, newer antifungal agents are needed to effectively treat invasive disease, and at the same time minimize adverse effects from therapy. The echinocandins comprise a novel class of antifungals; their mechanism of action involves inhibiting 1,3-beta-D-glucan synthase, ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.10.1479

    authors: Kim R,Khachikian D,Reboli AC

    更新日期:2007-07-01 00:00:00

  • New antiviral agents for the treatment of hepatitis C: ABT-450.

    abstract:INTRODUCTION:Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from stu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.889116

    authors: Carrion AF,Gutierrez J,Martin P

    更新日期:2014-04-01 00:00:00

  • Transdermal oxybutynin: a new treatment for overactive bladder.

    abstract::Overactive bladder has been successfully treated with oral anticholinergic drugs such as oxybutynin chloride. Although oral oxybutynin has been effective in controlling urinary urge incontinence and in decreasing incontinence episodes, adverse events, particularly dry mouth, often cause patients to discontinue oral th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.12.2315

    authors: Davila GW

    更新日期:2003-12-01 00:00:00

  • Ribavirin--current status of a broad spectrum antiviral agent.

    abstract::Ribavirin is a very broad-spectrum virustatic antiviral agent, first synthesised in 1972. It is characterised by low toxicity apart from reversible anaemia, usually mild. Its multiple mechanisms of action mean that viral resistance rarely develops. It can be administered orally, intravenously, or via a nebuliser. It h...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.8.1317

    authors: Snell NJ

    更新日期:2001-08-01 00:00:00

  • Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.

    abstract:AIM:To evaluate the efficacy and adverse effects of IDegLira and IGlarLixi treatment and to perform a comparison between two strategies. METHODS:The registration number is CRD42017053952. Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in ty...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/14656566.2017.1400011

    authors: Cai X,Gao X,Yang W,Ji L

    更新日期:2017-12-01 00:00:00

  • Aripiprazole for the treatment of irritability associated with autism.

    abstract:INTRODUCTION:Irritability (including tantrums, aggression and moodiness) is often associated with autistic disorder. Children with autism are frequently prescribed atypical antipsychotic medications for these behaviors. Although multiple agents have been found to be effective, the safety and tolerability of each antips...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.557661

    authors: Farmer CA,Aman MG

    更新日期:2011-03-01 00:00:00

  • Treatment of classical Hodgkin's lymphoma in children and adolescents.

    abstract:INTRODUCTION:The treatment of classical Hodgkin lymphoma (cHL) in children is a story of success. Nowadays, more than 90% of patients are cured and overall survival is nearly 100% at 5 years. Efforts have been made to avoid related effects of therapies; therefore, children are treated using different chemotherapy schem...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1606212

    authors: Gómez-Almaguer D,González-Llano O,Jiménez-Antolinez V,Gómez-De León A

    更新日期:2019-07-01 00:00:00

  • Oseltamivir: a clinical and pharmacological perspective.

    abstract::Oseltamivir is the ethyl ester prodrug of the antiviral molecule, oseltamivir carboxylate, a potent and selective inhibitor of influenza A and B neuraminidase (NA) (sialidase). It is highly bioavailable in capsule and suspension formulations and, after conversion to the active metabolite in the liver, distributes thro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.10.1671

    authors: Doucette KE,Aoki FY

    更新日期:2001-10-01 00:00:00

  • Recent important trials of pharmacotherapy in Parkinson's disease.

    abstract::Parkinson's disease (PD) affects approximately 1% of individuals > 60 years. Of these PD patients approximately 40% suffer dementia in later life. Levodopa is commonly used in the treatment of PD. Experimental evidence suggests that the dopamine synthesised from levodopa may contribute to the further degeneration of d...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.6.1025

    authors: Doggrell SA

    更新日期:2005-06-01 00:00:00

  • Cardiac sodium channels and inherited electrophysiological disorders: an update on the pharmacotherapy.

    abstract:INTRODUCTION:Since the recognition of inherited sodium (Na(+)) channel disease, the cardiac Na(+) channel has been extensively studied. Both loss-of-function and gain-of-function mutations of the cardiac Na(+) channel are associated with cardiac arrhythmia and sudden cardiac death. Pathophysiological mechanisms that ma...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.936380

    authors: van Hoeijen DA,Blom MT,Tan HL

    更新日期:2014-09-01 00:00:00

  • Short-term medical management of hydrocephalus.

    abstract::Hydrocephalus is an excess accumulation of cerebrospinal fluid in or around the brain that can be produced by a broad spectrum of disorders. It can develop at any age and its incidence is increasing, both in infants and adults. Although the standard treatment of hydrocephalus is cerebrospinal fluid shunting, there are...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.9.1525

    authors: Poca MA,Sahuquillo J

    更新日期:2005-08-01 00:00:00

  • Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials.

    abstract::Until recently, atorvastatin was known only as a new but more potent statin ('me too' drug) for lowering low-density lipoprotein cholesterol. In the last 2 years, data has become available on nearly 32,000 patients, in clinical settings ranging from primary prevention to acute coronary syndromes. These trials show the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.6.915

    authors: Ray KK,Cannon CP

    更新日期:2005-06-01 00:00:00

  • Differences between long-acting insulins for the treatment of type 2 diabetes.

    abstract:IMPORTANCE OF THE FIELD:Most guidelines suggest that failure of oral antidiabetic drugs should be followed by the addition of a basal insulin with aggressive titration of the dose. In most countries, neutral protamine Hagedorn (NPH)-insulin, glargine and detemir are the only choices. Clinical trials show that the metab...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.494831

    authors: Jensen MG,Hansen M,Brock B,Rungby J

    更新日期:2010-08-01 00:00:00

  • Orlistat in the treatment of obesity.

    abstract::Orlistat (Xenical, Hoffmann-La Roche) is a powerful inhibitor of gastrointestinal lipase and as such, reduces fat absorption. Unlike other weight-reducing drugs it is minimally absorbed and has no effects in the CNS. Orlistat is indicated for patients with a body mass index (BMI) of at least 30 kg/m2 or 28 kg/m2 in th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.4.841

    authors: Ballinger A

    更新日期:2000-05-01 00:00:00

  • Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.

    abstract:INTRODUCTION:Irritable bowel syndrome (IBS) treatment is challenging physicians because of its multifactorial physiopathology. In particular, abdominal pain and diarrhea management lack one unique effective pharmacological remedy. Opioid receptors, present in the central nervous system (CNS) and the enteric nervous sys...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1182982

    authors: Scarpellini E,Laterza L,Ianiro G,Tack J,Abenavoli L,Gasbarrini A

    更新日期:2016-07-01 00:00:00

  • Vinflunine for the treatment of breast cancer.

    abstract:INTRODUCTION:Breast cancer is the most frequently diagnosed cancer and the highest cause of cancer mortality in females worldwide. The development of drugs improving overall survival in late-stage metastatic breast cancer remains a challenge. Vinflunine is the most recently developed drug in the vinca alkaloid class. I...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1217991

    authors: Gourmelon C,Bourien H,Augereau P,Patsouris A,Frenel JS,Campone M

    更新日期:2016-09-01 00:00:00